• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

    128.20 -0.37 (-0.29%)
    Streaming Delayed Price Updated: 10:21 AM EDT, Jul 9, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Mirum Pharmaceuticals, Inc. - common stock

    < Previous 1 2 3 4 5 6 Next >
    News headline image
    Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance ↗
    Mirum Pharmaceuticals (NASDAQ:MIRM) executives said the rare disease company is entering a catalyst-heavy period, with recent positive clinical updates, ongoing commercial momentum for LIVMARLI and... 
    Via MarketBeat
    News headline image
    Mirum Pharma: A Rare Disease Growth Story to Watch ↗
    Mirum stock pulled back after earnings despite strong growth. Here’s why investors still see upside in the rare disease biotech company 
    Via MarketBeat
    News headline image
    Penn Capital Unloads 1.13 Million RealReal Shares Following Massive Stock Run-Up ↗
    This online marketplace connects U.S. consumers with consigned luxury goods, spanning apparel, jewelry, art, and home products. 
    Via The Motley Fool
    Topics Artificial Intelligence Regulatory Compliance
    News headline image
    Mirum (MIRM) Q1 2026 Earnings Call Transcript ↗
    Mirum (MIRM) Q1 2026 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Dips After Q1 Revenue Beat and Guidance Raise, Despite Massive IPR&D Charge ↗
    Via Chartmill
    News headline image
    2 Under-the-Radar Biotech Stocks Worth Buying for the Long Term ↗
    Vertex Pharmaceuticals has given Mirum Pharmaceuticals the blueprint for success in rare diseases. 
    Via The Motley Fool
    News headline image
    Prediction: Buying This Biotech Stock Today Could Set You Up for Life ↗
    This small biotech could grow much larger with some good news from its pipeline. 
    Via The Motley Fool
    News headline image
    Mirum (MIRM) Q2 2025 Earnings Call Transcript ↗
    Mirum (MIRM) Q2 2025 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Mirum Pharma (MIRM) Earnings Call Transcript ↗
    Mirum Pharma (MIRM) Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    Mirum Pharmaceuticals (NASDAQ:MIRM) Reports Q4 2025 Revenue Beat and 2026 Outlook ↗
    Via Chartmill
    MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Embodies the Minervini Growth Momentum Strategy ↗
    Via Chartmill
    News headline image
    Mirum (MIRM) Q1 2025 Earnings Call Transcript ↗
    Mirum (MIRM) Q1 2025 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings Intellectual Property
    News headline image
    Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 ↗
    This clinical-stage biotech develops precision therapies for genetically defined diseases, targeting rare cancers and systemic mastocytosis. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position ↗
    This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms. 
    Via The Motley Fool
    Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Offers a High-Growth Momentum and Technical Breakout Setup ↗
    Via Chartmill
    MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Shows Strong Growth Momentum and Bullish Technical Setup ↗
    Via Chartmill
    News headline image
    Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy? ↗
    HealthEquity delivers cloud-based healthcare savings solutions to employers and individuals, with a broad client network across the U.S. 
    Via The Motley Fool
    News headline image
    Small-Cap Shudder: Russell 2000’s 1.9% Slide Signals Cracks in Economic Resilience
    NEW YORK — The euphoric "small-cap comeback" that defined the opening weeks of 2026 came to a grinding halt on Thursday. The Russell 2000 index, the primary barometer for American small-cap health,... 
    Via MarketMinute
    Topics Artificial Intelligence Economy Energy
    News headline image
    Mirum (MIRM) Q4 2025 Earnings Call Transcript ↗
    Mirum (MIRM) Q4 2025 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    News headline image
    ACM Research’s AI Surge Collides With Export Controls and Chip Spending Cycles ↗
    Penn Capital initiated a position in ACM Research, which supplies cleaning and plating tools used in advanced semiconductor manufacturing. As AI-driven chip designs grow more complex, precision... 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition ↗
    Arcellx develops cell-based immunotherapies targeting cancer, with a lead candidate in early-stage trials for multiple myeloma. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough ↗
    Cogent Biosciences develops precision therapies for genetically defined diseases, with a pipeline targeting rare oncological conditions. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge ↗
    This clinical-stage biotech develops therapies for NASH and obesity, advancing a diverse pipeline of small-molecule drug candidates. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Is Mirum Pharmaceuticals on a Strong Path to Profitability? ↗
    The drugmaker is doing nearly everything else right. 
    Via The Motley Fool
    News headline image
    Is Mirum Pharmaceuticals About to Soar in 2026? ↗
    The future looks bright for this high-flying biotech stock. 
    Via The Motley Fool
    News headline image
    A New Era in Rare Hepatology: The Deep-Dive Analysis of Mirum Pharmaceuticals (MIRM)
    Date: January 13, 2026 Introduction Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) has reached a critical inflection point, evolving from a speculative clinical-stage biotech into a commercial-stage... 
    Via PredictStreet
    Topics Economy Initial Public Offering
    News headline image
    3 Top Growth Stocks to Buy in the First Half of 2026 ↗
    Don't wait too long to make a decision on these three stocks. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Mirum Director Sells $400K Amid 91% Stock Surge -- Here's What the Firm Expects for 2026 ↗
    Focused on rare liver disease therapies, this biopharma company reported a significant insider sale amid strong one-year stock gains. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    5 Predictions for the Stock Market in 2026 -- and Which Stocks Will Soar the Most If They're Right ↗
    Not all of these predictions may come true. But at least a few of them will likely do so. 
    Via The Motley Fool
    Topics Artificial Intelligence Economy
    News headline image
    Prediction: 3 Stocks That Will Be Worth More Than Newsmax 5 Years From Now ↗
    These predictions were easy. 
    Via The Motley Fool
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.